Durability of Immune Responses After Boosting in Ad26.COV2.S-Primed Healthcare Workers

SWITCH Research Group; Roos S.G. Sablerolles; Wim J.R. Rietdijk; Abraham Goorhuis; Douwe F. Postma; Leo G. Visser; Katharina S. Schmitz; Daryl Geers; Susanne Bogers; Eva van Haren; Marion P.G. Koopmans; Virgil A.S.H. Dalm; Neeltje A. Kootstra; Anke L.W. Huckriede; Renate Akkerman; Martin Beukema; Melvin Lafeber; Debbie van Baarle; Rory D. de Vries; P. Hugo M. van der Kuy; Corine H. GeurtsvanKessel

doi:10.1093/cid/ciac495

Durability of Immune Responses After Boosting in Ad26.COV2.S-Primed Healthcare Workers

SWITCH Research Group
, Roos S.G. Sablerolles
, Wim J.R. Rietdijk
, Abraham Goorhuis
, Douwe F. Postma
, Leo G. Visser
, Katharina S. Schmitz
, Daryl Geers
, Susanne Bogers
, Eva van Haren
, Marion P.G. Koopmans
, Virgil A.S.H. Dalm
, Neeltje A. Kootstra
, Anke L.W. Huckriede
, Renate Akkerman
, Martin Beukema
, Melvin Lafeber
, Debbie van Baarle
, Rory D. de Vries
, P. Hugo M. van der Kuy

Corine H. GeurtsvanKessel^*

^*Corresponding author for this work

Amsterdam UMC
University of Amsterdam
Leiden University Medical Centre
University Medical Centre Groningen
National Institute of Public Health and the Environment

Research output: Contribution to journal › Article › Academic › peer-review

11 Citations (Scopus)

60 Downloads (Pure)

Abstract

The emergence of SARS-CoV-2 variants raised questions regarding the durability of immune responses after homologous or heterologous boosters after Ad26.COV2.S-priming. We found that SARS-CoV-2-specific binding antibodies, neutralizing antibodies, and T cells are detectable 5 months after boosting, although waning of antibodies and limited cross-reactivity with Omicron BA.1 was observed.

Original language	English
Article number	ciac495
Pages (from-to)	e533-e536
Journal	Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Volume	76
Issue number	3
Early online date	20 Jun 2022
DOIs	https://doi.org/10.1093/cid/ciac495
Publication status	Published - 1 Feb 2023

Bibliographical note

Funding Information:
The SWITCH trial was funded by a grant (10430072110001) from ZonMw.

Publisher Copyright:
© 2022 The Author(s). Published by Oxford University Press on behalf of Infectious Diseases Society of America.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1093/cid/ciac495Licence: CC BY-NC-ND

ciac495Final published version, 503 KBLicence: CC BY-NC-ND

Cite this

SWITCH Research Group, Sablerolles, R. S. G., Rietdijk, W. J. R., Goorhuis, A., Postma, D. F., Visser, L. G., Schmitz, K. S., Geers, D., Bogers, S., van Haren, E., Koopmans, M. P. G., Dalm, V. A. S. H., Kootstra, N. A., Huckriede, A. L. W., Akkerman, R., Beukema, M., Lafeber, M., van Baarle, D., de Vries, R. D., ... GeurtsvanKessel, C. H. (2023). Durability of Immune Responses After Boosting in Ad26.COV2.S-Primed Healthcare Workers. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 76(3), e533-e536. Article ciac495. https://doi.org/10.1093/cid/ciac495

@article{26e22549f8a847e6a37c0d65ab3a6cf3,

title = "Durability of Immune Responses After Boosting in Ad26.COV2.S-Primed Healthcare Workers",

abstract = "The emergence of SARS-CoV-2 variants raised questions regarding the durability of immune responses after homologous or heterologous boosters after Ad26.COV2.S-priming. We found that SARS-CoV-2-specific binding antibodies, neutralizing antibodies, and T cells are detectable 5 months after boosting, although waning of antibodies and limited cross-reactivity with Omicron BA.1 was observed.",

author = "\{SWITCH Research Group\} and Sablerolles, \{Roos S.G.\} and Rietdijk, \{Wim J.R.\} and Abraham Goorhuis and Postma, \{Douwe F.\} and Visser, \{Leo G.\} and Schmitz, \{Katharina S.\} and Daryl Geers and Susanne Bogers and \{van Haren\}, Eva and Koopmans, \{Marion P.G.\} and Dalm, \{Virgil A.S.H.\} and Kootstra, \{Neeltje A.\} and Huckriede, \{Anke L.W.\} and Renate Akkerman and Martin Beukema and Melvin Lafeber and \{van Baarle\}, Debbie and \{de Vries\}, \{Rory D.\} and \{van der Kuy\}, \{P. Hugo M.\} and GeurtsvanKessel, \{Corine H.\}",

note = "Funding Information: The SWITCH trial was funded by a grant (10430072110001) from ZonMw. Publisher Copyright: {\textcopyright} 2022 The Author(s). Published by Oxford University Press on behalf of Infectious Diseases Society of America.",

year = "2023",

month = feb,

day = "1",

doi = "10.1093/cid/ciac495",

language = "English",

volume = "76",

pages = "e533--e536",

journal = "Clinical infectious diseases : an official publication of the Infectious Diseases Society of America",

issn = "1058-4838",

publisher = "Oxford University Press",

number = "3",

}

SWITCH Research Group, Sablerolles, RSG , Rietdijk, WJR, Goorhuis, A, Postma, DF, Visser, LG, Schmitz, KS, Geers, D, Bogers, S, van Haren, E, Koopmans, MPG , Dalm, VASH, Kootstra, NA, Huckriede, ALW, Akkerman, R, Beukema, M, Lafeber, M, van Baarle, D, de Vries, RD , van der Kuy, PHM & GeurtsvanKessel, CH 2023, 'Durability of Immune Responses After Boosting in Ad26.COV2.S-Primed Healthcare Workers', Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, vol. 76, no. 3, ciac495, pp. e533-e536. https://doi.org/10.1093/cid/ciac495

Durability of Immune Responses After Boosting in Ad26.COV2.S-Primed Healthcare Workers. / SWITCH Research Group ; Sablerolles, Roos S.G.; Rietdijk, Wim J.R. et al.
In: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, Vol. 76, No. 3, ciac495, 01.02.2023, p. e533-e536.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Durability of Immune Responses After Boosting in Ad26.COV2.S-Primed Healthcare Workers

AU - SWITCH Research Group

AU - Sablerolles, Roos S.G.

AU - Rietdijk, Wim J.R.

AU - Goorhuis, Abraham

AU - Postma, Douwe F.

AU - Visser, Leo G.

AU - Schmitz, Katharina S.

AU - Geers, Daryl

AU - Bogers, Susanne

AU - van Haren, Eva

AU - Koopmans, Marion P.G.

AU - Dalm, Virgil A.S.H.

AU - Kootstra, Neeltje A.

AU - Huckriede, Anke L.W.

AU - Akkerman, Renate

AU - Beukema, Martin

AU - Lafeber, Melvin

AU - van Baarle, Debbie

AU - de Vries, Rory D.

AU - van der Kuy, P. Hugo M.

AU - GeurtsvanKessel, Corine H.

N1 - Funding Information: The SWITCH trial was funded by a grant (10430072110001) from ZonMw. Publisher Copyright: © 2022 The Author(s). Published by Oxford University Press on behalf of Infectious Diseases Society of America.

PY - 2023/2/1

Y1 - 2023/2/1

N2 - The emergence of SARS-CoV-2 variants raised questions regarding the durability of immune responses after homologous or heterologous boosters after Ad26.COV2.S-priming. We found that SARS-CoV-2-specific binding antibodies, neutralizing antibodies, and T cells are detectable 5 months after boosting, although waning of antibodies and limited cross-reactivity with Omicron BA.1 was observed.

AB - The emergence of SARS-CoV-2 variants raised questions regarding the durability of immune responses after homologous or heterologous boosters after Ad26.COV2.S-priming. We found that SARS-CoV-2-specific binding antibodies, neutralizing antibodies, and T cells are detectable 5 months after boosting, although waning of antibodies and limited cross-reactivity with Omicron BA.1 was observed.

UR - https://www.scopus.com/pages/publications/85147783363

U2 - 10.1093/cid/ciac495

DO - 10.1093/cid/ciac495

M3 - Article

C2 - 35723273

SN - 1058-4838

VL - 76

SP - e533-e536

JO - Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

JF - Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

IS - 3

M1 - ciac495

ER -

Durability of Immune Responses After Boosting in Ad26.COV2.S-Primed Healthcare Workers

Abstract

Bibliographical note

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this